About My Health Careers Internship MedBlogs Contact us

Novel Targets for Diabetes Drug Development

by Jayashree on August 31, 2007 at 3:54 PM
Font : A-A+

Novel Targets for Diabetes Drug Development

A team of researchers have determined the structure of a protein, which is considered to be the possible target for the development of drugs to treat diabetes.

The researchers have discovered the three-dimensional structure of a protein MitoNEET, which was previously identified as a spot where diabetes drugs could operate.


The discovery makes it possible to design small molecules that interact with it and modify its function. The researchers say that MitoNEET has a novel three-dimensional structure that makes it a particularly interesting candidate for the design of innovative compounds that can bind to it.

"This is the first time that a protein like this has ever been found," said Patricia Jennings, a professor in UCSD's department of Chemistry and Biochemistry who led the study along with Mark Paddock, a project scientist in UCSD's Physics department.

"It is a brand new structure, a unique beast, which makes it an exciting target for structure-based drug design. We are grateful about the highly collaborative spirit of the UCSD community that brought such diverse expertise and helped us tackle such a complex project," Jennings added.

"Our work may provide a basis for the design of newer diabetes drugs that have potentially greater specificity and fewer side effects than existing ones," added Paddock.

Following the initial work of co-authors Sandra Wiley, Anne Murphy and Jack Dixon at UCSD's School of Medicine, and in collaboration with Herbert Axelrod and Aina Cohen at the Stanford Synchrotron Radiation Laboratory and Rachel Nechushtai at the Hebrew University of Jerusalem, also co-authors on the paper, the team determined that mitoNEET is an iron-sulphur protein.

MitoNEET's iron-sulphur cluster is loosely bound, a property that may be linked to one of its functions. When mitoNEET binds the type 2 diabetes drug Actos, the iron-sulphur cluster becomes more stable. This drug was thought to work through an entirely different mechanism involving a different protein.

However, the finding by Jerry Colca, presently at Metabolic Solutions Development Company in Kalamazoo, Michigan, that the thiazolidinediones—the class of diabetes drugs of which Actos is a member—bind to mitoNEET indicated a possible mechanism involving mitoNEET. Colca's finding inspired the UCSD-led study, which suggests that Actos and similar drugs may protect cells from the damaging effects of free iron by keeping the iron-sulphur cluster attached to mitoNEET.

From mitoNEET's structure, location and properties, it could also play a role as a sensor of oxidative stress in the cell. Oxidative stress is a problem in many diseases including diabetes. MitoNEET is confined to the mitochondria—structures within cells that convert nutrients into energy—where reactive compounds accumulate as nutrients are metabolized. MitoNEET's structure would allow it to transfer electrons to and from, and therefore detect, these compounds.

"MitoNEET may be an example of an ever increasing group of proteins found to have more than one function. I think we are at the beginning of what is sure to be an interesting and biologically important puzzle." said Paddock.

"It is intriguing to see these different pieces coming together. There is growing evidence that mitochondrial dysfunction and compromised oxidative capacity is a problem in diabetes. MitoNEET has iron-sulphur clusters that can transfer electrons, and it binds insulin-sensitizing drugs. Now that we know the structure and physical properties of the protein we can use this knowledge for drug studies and studies of biological function," explained Jennings.

The team plans to use the new structural information for designing more sophisticated experiments to test function and structure-based drug design to create drugs that interact better with mitoNEET.

"This work is a great example of the possible synergies of a multidisciplinary and multinational effort. Instrumental in these results were the combined efforts of the US and Israeli teams," said Paddock.

The study is published in the September 4 issue of the journal Proceedings of the National Academy of Sciences.

Source: ANI

News A-Z
News Category
What's New on Medindia
January is the Thyroid Awareness Month in 2022
Menstrual Disorders
Coffee May Help You Fight Endometrial Cancer
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Diabetic Retinopathy Drug Toxicity Diabetes Diabetic Diet Diabetes - Essentials Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices Diabetes and Exercise Signature Drug Toxicity Stress Relief Through Alternative Medicine 

Recommended Reading
Diabetes Drug to Carry 'black Box' Warning of Congestive Heart Failure Risk
The US Food and Drug Administration has announced that the wrappers of the diabetes drug Avandia ......
A comprehensive article on diabetes - both Type 1 and Type 2 diabetes, including : causes, signs, sy...
Diabetes - Essentials
Diabetes is a metabolic disease caused by insulin deficiency that leads to high blood sugar levels a...
Diabetes - Self-Monitoring of Blood Glucose (SMBG)
Self-Monitoring Of Blood Glucose (SMBG) is one of the greatest advancements in the management of Di...
Diabetes and Exercise
Regular exercise especially in type II diabetes not only helps reduce the sugar but also reduces the...
Diabetic Diet
The diabetic diet most often recommended is high in dietary fiber (especially soluble fiber) and nut...
Diabetic Retinopathy
The term ‘diabetic retinopathy’ refers to changes in the retina which often occur in people with ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Insulin Delivery Devices
Insulin delivery devices have evolved drastically since their invention in 1922. They are all aimed ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)